Up­dat­ed: $100B+ in sav­ings? Why the in­com­ing Hu­mi­ra biosim­i­lars will take time to catch on

The 20-year reign of Ab­b­Vie’s best-sell­ing bi­o­log­ic of all time — the au­toim­mune dis­ease bi­o­log­ic Hu­mi­ra (adal­i­mum­ab) that has brought in up­wards of $200 bil­lion dur­ing its mo­nop­oly — is com­ing to an end to­mor­row with the launch of Am­gen’s biosim­i­lar Am­je­vi­ta.

The launch comes more than four years af­ter Eu­rope saw the ex­act same com­pe­ti­tion, lead­ing to steep dis­counts in price, high­er up­take, and big cost sav­ings across the board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER